ADMA BIOLOGICS, INC.
ADMANasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $510.2M | $426.5M | $258.2M | $154.1M | $80.9M | $42.2M |
| Operating income | $191.4M | $139.0M | $21.6M | −$39.4M | −$58.4M | −$64.9M |
| Net income | $146.9M | $197.7M | −$28.2M | −$65.9M | −$71.6M | −$75.7M |
| Total assets | $624.2M | $488.7M | $329.2M | $348.5M | $276.3M | $207.7M |
| Total liabilities | $146.9M | $139.7M | $194.0M | $196.5M | $135.1M | $119.4M |
| Equity | $477.3M | $349.0M | $135.2M | $152.0M | $141.2M | $88.2M |
| EPS (diluted) | $0.60 | $0.81 | $-0.13 | $-0.33 | $-0.51 | $-0.88 |
| Shares out. | 237.6M | 228.2M | 222.2M | 195.9M | 121.3M | 86.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 37.5%
- Net margin
- 28.8%
- Return on equity
- 30.8%
- Return on assets
- 23.5%
- Return on capital (ROCE)
- 34.5%
- Liabilities / assets
- 23.5%
- Debt / equity
- 0.31×
- Book value / share
- $2.01
- Revenue growth (YoY)
- 19.6%
- Net income growth (YoY)
- −25.7%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 8.80safe
- Accruals / assets
- 15.5%high accruals
- Beneish M-Score
- -0.17elevated
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 6 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High accruals — earnings-quality risk
- Beneish M-Score elevated — earnings-manipulation screen flag
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 3, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Invesco Ltd.Passive (13G)Feb 12, 2026
- State Street CorpPassive (13G)Aug 11, 2025
- Blackrock, Inc.Passive (13G)Apr 30, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Grossman Jerrold BDirector | May 27, 2026 | Buy | 6,400 | $7.91 |
| Grossman Jerrold BDirector | May 12, 2026 | Buy | 12,500 | $8.01 |
| Grossman Jerrold BDirector | May 11, 2026 | Buy | 12,500 | $8.01 |
| Kestenberg-Messina Kaitlin M.Officer — COO and SVP, Compliance | Apr 1, 2026 | Tax withholding | 20,362 | $9.11 |
| Guiheen Lawrence P.Director | Mar 13, 2026 | Option exercise | 30,000 | $3.66 |
| Grossman Adam SOfficer — President and CEO | Mar 16, 2026 | Option exercise | 15,000 | $5.40 |
| Kestenberg-Messina Kaitlin M.Officer — COO and SVP, Compliance | Mar 6, 2026 | Tax withholding | 10,059 | $15.39 |
| Grossman Adam SOfficer — President and CEO | Mar 6, 2026 | Tax withholding | 56,438 | $15.39 |
| Elms SteveDirector | Mar 5, 2026 | Buy | 7,000 | $15.67 |
| Grossman Adam SOfficer — President and CEO | Feb 26, 2026 | Tax withholding | 54,858 | $15.18 |
| Kestenberg-Messina Kaitlin M.Officer — COO and SVP, Compliance | Feb 19, 2026 | Tax withholding | 8,161 | $16.32 |
| Grossman Adam SOfficer — President and CEO | Feb 19, 2026 | Tax withholding | 24,793 | $16.32 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 20.0M | 2.3 | -3.2% |
| Apr 30, 2026 | 20.7M | 3.2 | +7.0% |
| Apr 15, 2026 | 19.3M | 3.8 | -12.9% |
| Mar 31, 2026 | 22.2M | 1.6 | -14.1% |
| Mar 13, 2026 | 25.8M | 7.1 | +35.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 6, 2026
- Other material eventMay 4, 2026
- Regulation FD disclosureMar 27, 2026
- Regulation FD disclosure · Other material eventMar 2, 2026
- Results of operations · Director / officer changeFeb 25, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Results of operationsNov 5, 2025
- Entered a material agreement · Terminated a material agreement · Results of operations · New financial obligationAug 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.